Loading
Synnovation Therapeutics develops targeted pills for genetically defined cancers. Its PARP1 blocker SNV1521, built to reach the brain, is in early trials including one with a RAS drug in pancreatic cancer; in 2026 Novartis agreed to buy its breast cancer PI3K-alpha programme for USD 2 billion upfront.
Synnovation Therapeutics, with its main office in Wilmington, Delaware, launched on 24 January 2024 with a USD 102 million Series A led by Third Rock Ventures with Nextech, Lilly Asia Ventures, Sirona Capital and Cormorant Asset Management, to advance small-molecule precision oncology medicines. SNV1521 is a PARP1-selective, brain-penetrant inhibitor; its first patient was dosed on 11 March 2024, phase 1 data were presented at ESMO 2025, and a clinical collaboration with DualityBio on the HER3 antibody-drug conjugate DB-1310 was announced in October 2025. A further phase 1 study combines SNV1521 with the RAS(ON) inhibitor daraxonrasib in advanced pancreatic cancer. SNV4818, a pan-mutant-selective PI3Kα inhibitor, dosed its first patient on 24 February 2025; on 20 March 2026 Novartis agreed to acquire Pikavation Therapeutics, the wholly owned subsidiary holding the PI3Kα programmes, for USD 2 billion upfront and up to USD 1 billion in milestones, with Synnovation keeping SNV1521 and its other subsidiaries. Wenqing Yao is founder and chief executive and Liangxing Wu is co-founder.
| Round | Year | Amount | Source |
|---|---|---|---|
| Series A · Led by Third Rock Ventures with Nextech, Lilly Asia Ventures, Sirona Capital and Cormorant Asset Management | 2024 | $102M | synnovationtx.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
SNV1521 is an experimental pill being studied to block a DNA-repair enzyme in cancer cells.
Shares Third Rock Ventures, Cormorant Asset Management, PI3K, AKT and mTOR inhibitors, PIK3CA / PI3K-alpha.
Shares Third Rock Ventures, Cormorant Asset Management, Synthetic lethality approaches, PARP inhibitors.
Shares Cormorant Asset Management, PIK3CA / PI3K-alpha, HR-positive / HER2-negative breast cancer.
Shares Synthetic lethality approaches, PARP inhibitors, PARP, Pancreatic ductal adenocarcinoma.
Shares Synthetic lethality approaches, PARP inhibitors, PARP.
Shares Synthetic lethality approaches, PARP inhibitors, PARP.
Shares PI3K, AKT and mTOR inhibitors, PIK3CA / PI3K-alpha, Novartis, HR-positive / HER2-negative breast cancer.
Shares Synthetic lethality approaches, PARP inhibitors, PARP.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/